Trevena INC

Trevena, Inc. has settled its royalty-based loan agreement with R-Bridge Investment Four Pte. Ltd. by assigning its China royalty rights for Olinvyk, while retaining commercialization milestone payments.

Trevena, Inc. enters into a securities exchange agreement to exchange outstanding warrants for cash, common stock, and a new pre-funded warrant.

Trevena, Inc. implements cost-cutting measures including a director's resignation, an officer's termination, and a subsequent consulting agreement with the terminated officer.

Trevena, Inc. has ceased the sale of its remaining OLINVYK dosage strengths, citing business and financial considerations.

Trevena Inc. has appointed Katrine Sutton as its new principal financial officer and principal accounting officer, effective November 26, 2024, replacing Barry Shin.

Trevena reported a net loss of $4.9 million for Q3 2024, alongside significant cost-cutting measures including executive departures and a board reduction.

Trevena Inc. reported its Q3 2024 financial results, highlighting a net loss and ongoing strategic review, alongside significant cost-cutting measures including executive departures and a reverse stock split.

Trevena Inc. announced its second quarter 2024 financial results, highlighting a strategic review process and reduced commercial support for its lead product, OLINVYK.

Trevena Inc. announced its first quarter 2024 financial results, highlighting a strategic review of its commercial operations for OLINVYK and ongoing efforts to maintain Nasdaq listing compliance.

Trevena Inc.'s 2023 annual report reveals a company in transition, reducing commercial support for its only approved product, OLINVYK, while exploring strategic alternatives to preserve capital.

Mark Demitrack, Acting CMO of Trevena Inc., reports the disposal of common stock to cover tax obligations upon the vesting of restricted stock units.

Barry Shin, Acting COO and CFO of Trevena Inc., reports the disposal of common stock to cover tax obligations upon the vesting of restricted stock units.

Carrie L. Bourdow, Acting CEO of Trevena Inc., reports the withholding of shares to cover tax obligations upon the vesting of restricted stock units.

Robert Yoder, SVP and Chief Business Officer of Trevena Inc., reports the withholding of 487 common stock shares to cover tax obligations related to vested restricted stock units and performance stock units.

Barry Shin, CFO of Trevena Inc., reports the withholding of shares to cover tax obligations related to the vesting and settlement of restricted stock units.

Director Scott Braunstein acquired stock options for 13,700 shares of Trevena Inc. (TRVN) on June 13, 2024.

Trevena Inc. files an amendment to its definitive proxy statement to correct the quorum requirement for its upcoming Annual Meeting of Stockholders.

Trevena Inc. has amended its definitive proxy statement to clarify the voting standard for Proposal 5, concerning a potential reverse stock split, and the impact of abstentions and broker non-votes.

Trevena, Inc. is asking stockholders to approve a reverse stock split and an amendment to its equity incentive plan at the upcoming annual meeting.

Trevena, Inc. has adjourned its Special Meeting of Stockholders to April 19, 2024, to allow for additional solicitation time regarding a proposal to authorize the issuance of common stock underlying certain warrants.

Trevena Inc. has adjourned its Special Meeting of Stockholders due to a lack of quorum and will reconvene on April 19, 2024, after further soliciting votes.

Armistice Capital, LLC and Steven Boyd report acquiring a 9.91% beneficial ownership stake in Trevena, Inc., holding 95,000 shares.